Global Genetic Testing Market (2020 to 2026) - Featuring Abbott Laboratories, 23andMe & Cepheid Among Others

USA - English

News provided by

Jul 02, 2021, 12:00 ET

DUBLIN, July 2, 2021 /PRNewswire/ -- The "Genetic Testing Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.

The global genetic testing market is growing at a significant CAGR during the forecast period. The genetic disorder can be occurred by a change in one gene (monogenic disorder), by changes in multiple genes by a combination of environmental factors, and gene mutations, or by the destruction of chromosomes. Genetic testing is a medical test that is used for the identification of mutations in genes or chromosomes. The key benefit of genetic testing is the chance to know the risk for a certain disease that possibly can be prevented, identify the disease or a type of disease, identify the cause of a disease, to determine options for a disease. The disease that can be identified by genetic testing includes, breast and ovarian cancer, Age-Related Macular Degeneration (AMD), bipolar disorder, Parkinson's disease, celiac disease, and psoriasis.

The global genetic testing market is projected to considerably grow in the upcoming year due to the prevalence of genetic disorders, cancer, and chronic disease. Moreover, continuous advancement by the medical companies in the genetic diagnostic field is also augmenting the market growth. These companies are finding new and better tests for the accurate diagnosis of the most prevalent as well as rare diseases. Besides, the increase in awareness between people about health and the increased mortality rate due to genetic diseases across the globe is also a major factor increasing the need for demand for genetic testing.

Moreover, The adoption of (DTC) direct-to-consumer genetic testing kits in countries such as the US, China, and Japan, is increasing rapidly. With growing technological acceptances, awareness programs, and a drop in costs, the market for DTC-GT kits is likely to witness a significant boost over the forecast period. However, the lack of diagnostic infrastructure in emerging economies is a challenging factor for market growth.

Segmental Outlook

The global genetic testing market is segmented by technology, type, and disease. By technology, the market is segmented into polymerase chain reaction, DNA sequencing, cytogenetics (karyotyping and fish), microarrays, and gene expression profiling. By type, the market is divided into prenatal and newborn genetic testing, predictive testing, diagnostic testing, carrier testing, and others. Moreover, by disease type, the market is sub-segmented into cancer, Alzheimer's and Parkinson's, Fanconi anemia, sickle cell anemia, cardiovascular diseases, and others.

Global Genetic Testing Market Share by Disease, 2020 (%)

Based on disease type, cancer segment is expected to hold a major market share during the forecast period. The need for accurate testing for cancer at the early stages and prediagnostic testing are some of the major factors for the significant market share of the segment. It is since the number of the cancer patient are very high, government and companies are trying to increase the 5-year survival rate of fatal cancers. Genetic testing aids in estimate a person's chance of developing cancer in a lifetime. Genetic tests are available for some types of cancer. These include breast cancer, ovarian cancer, colon cancer, thyroid cancer, prostate cancer, pancreatic cancer, melanoma, sarcoma, kidney cancer, and stomach cancer.

Regional Outlooks

The global genetic testing market is analyzed on the basis of the geographical regions that are contributing significantly to the growth of the market. The market report covers the analysis of four major regions into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to contribute a significant share in the global genetic testing market due to the high awareness among the people about advanced treatment for healthcare, well-developed healthcare infrastructure, presence of key players, and availability of drugs. Moreover, an increase in government initiatives for the enhancement of healthcare facilities and funding in research in the region is also a major factor for the significant market share of the region. In the US under the US CDC EGAPP, inventiveness has been taken by the government such as the Evaluation of Genomic Applications in Practice and Prevention which is also motivating the market growth. One of the key goals of the initiative is to timely, offer objectively, and credible information that is linked to available scientific evidence. These statistics will allow healthcare workers and payers, customers, policymakers, and others to differentiate genetic tests that are safe and useful.

Global Genetic Testing Market Growth, by Region 2020-2026

Asia-Pacific will have considerable growth in the global Genetic Testing Market
In Asia Pacific, the market is increasing due to government initiatives in research and the increasing prevalence of chronic diseases. Apart from cancer, genetic testing processes have also come in easy reach for the diagnosis of inherited cardiovascular diseases such as cardiac amyloidosis, Brugada syndrome, and familial dilated cardiomyopathy. As the region has a high incidence of cardiovascular diseases, significant scope for genetic testing can be witnessed in the region during the forecast period.

Market Players Outlook

The report covers the analysis of various players operating in the global genetic testing market. Some of the major players covered in the report include Abbott Laboratories, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., and Thermo Fisher Scientific, Inc. To survive in the market, these players adopt different marketing strategies such as mergers and acquisitions, product launches, and geographical expansion.

Recent Activity

In August 2020, Roche announced the US FDA clearance of FoundationOne Liquid CDx, it's a comprehensive pan-tumor liquid biopsy test, Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to benefit inform treatment decisions for all solid tumor cancers.
In May 2020, Myriad Genetics, Inc. announced the US FDA approval of my choice CDx for the treatment of patients having Advanced Ovarian Cancer. MyChoice CDx uses as a companion diagnostic to identify women with advanced ovarian cancer.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global female infertility diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Key Companyanalysis
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Key Strategy Analysis

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Genetic Testing Market by Technology
5.1.1. Polymerase Chain Reaction
5.1.2. DNA Sequencing
5.1.3. Cytogenetics (Karyotyping and FISH)
5.1.4. Microarrays
5.1.5. Gene Expression Profiling
5.2. Global Genetic Testing Market by Type
5.2.1. Prenatal and New-Born Genetic Testing
5.2.2. Predictive Testing
5.2.3. Diagnostic Testing
5.2.4. Carrier Testing
5.2.5. Other (Forensic Testing, Pre-Implantation Testing)
5.3. Global Genetic Testing Market by Disease
5.3.1. Cancer
5.3.2. Alzheimer's and Parkinson's
5.3.3. Sickle Cell Anaemia
5.3.4. Fanconi Anaemia
5.3.5. Cardiovascular Disease
5.3.6. Others (Cystic Fibrosis, Duchenne's Muscular Dystrophy)

6. Regional Analysis
6.2. North America
6.2.1. United States
6.2.2. Canada
6.3. Europe
6.3.1. UK
6.3.2. Germany
6.3.3. Italy
6.3.4. Spain
6.3.5. France
6.3.6. Rest of Europe
6.4. Asia-Pacific
6.4.1. China
6.4.2. India
6.4.3. Japan
6.4.4. Rest of Asia-Pacific
6.5. Rest of the World

7. Company Profiles
7.1. 23Andme, Inc.
7.2. Abbott Laboratories
7.3. AutoGenomics, Inc.
7.4. Biocartis SA
7.5. Biomerieux SA
7.6. Bio-Rad Laboratories, Inc.
7.7. Cepheid, Inc.
7.8. Elitech Group
7.9. Eurofins Scientific SE
7.10. F. Hoffmann-La Roche Ltd.
7.11. Foundation Medicine, Inc.
7.12. Genomictree Inc.
7.13. Illumina, Inc.
7.14. Luminex Corp.
7.15. MedGenome, Inc.
7.16. Myriad Genetics, Inc.
7.17. NeoGenomics Laboratories, Inc.
7.18. Opko Health Inc.
7.19. PerkinElmer, Inc.
7.20. 7.19. Qiagen N.V.
7.21. 7.20. Quest Diagnostics, Inc.
7.22. Takara Bio, Inc.
7.23. Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/o583xw